Business Description
Jagsonpal Pharmaceuticals Ltd
ISIN : INE048B01035
Total Employee Number:
1,410Compare
Compare
Traded in other countries / regions
507789.India IPO Date
1991-10-10Description
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 13.01 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.12 | |||||
Interest Coverage | 47.31 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 23.64 | |||||
Beneish M-Score | -1.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.2 | |||||
3-Year EBITDA Growth Rate | 21.6 | |||||
3-Year EPS without NRI Growth Rate | 13.9 | |||||
3-Year FCF Growth Rate | -1.1 | |||||
3-Year Book Growth Rate | 19.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.02 | |||||
9-Day RSI | 44.8 | |||||
14-Day RSI | 48.47 | |||||
3-1 Month Momentum % | 15.37 | |||||
6-1 Month Momentum % | 40.48 | |||||
12-1 Month Momentum % | -8.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.06 | |||||
Quick Ratio | 4.54 | |||||
Cash Ratio | 3.75 | |||||
Days Inventory | 53.26 | |||||
Days Sales Outstanding | 22.42 | |||||
Days Payable | 39.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.13 | |||||
Dividend Payout Ratio | 0.38 | |||||
Forward Dividend Yield % | 1.13 | |||||
5-Year Yield-on-Cost % | 1.13 | |||||
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | 0.75 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.66 | |||||
Operating Margin % | 16.93 | |||||
Net Margin % | 15 | |||||
EBITDA Margin % | 23.67 | |||||
FCF Margin % | 16.25 | |||||
OCF Margin % | 16.3 | |||||
ROE % | 16.81 | |||||
ROA % | 14.46 | |||||
ROIC % | 24.13 | |||||
3-Year ROIIC % | 7.03 | |||||
ROC (Joel Greenblatt) % | 327.79 | |||||
ROCE % | 21.78 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 35.19 | |||||
PE Ratio without NRI | 33.92 | |||||
Shiller PE Ratio | 67.67 | |||||
Price-to-Owner-Earnings | 30.5 | |||||
PEG Ratio | 1.33 | |||||
PS Ratio | 5.29 | |||||
PB Ratio | 5.38 | |||||
Price-to-Tangible-Book | 7.5 | |||||
Price-to-Free-Cash-Flow | 32.49 | |||||
Price-to-Operating-Cash-Flow | 32.39 | |||||
EV-to-EBIT | 23.33 | |||||
EV-to-EBITDA | 20.09 | |||||
EV-to-Revenue | 4.76 | |||||
EV-to-FCF | 29.27 | |||||
Price-to-GF-Value | 1.08 | |||||
Price-to-Projected-FCF | 2.16 | |||||
Price-to-Median-PS-Value | 3.65 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.38 | |||||
Price-to-Graham-Number | 3.36 | |||||
| Price-to-Net-Current-Asset-Value | 14.49 | |||||
| Price-to-Net-Cash | 22.64 | |||||
Earnings Yield (Greenblatt) % | 4.29 | |||||
FCF Yield % | 3.19 | |||||
Forward Rate of Return (Yacktman) % | 22.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jagsonpal Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 2,872.25 | ||
| EPS (TTM) (₹) | 6.31 | ||
| Beta | 0.2655 | ||
| 3-Year Sharpe Ratio | 0.39 | ||
| 3-Year Sortino Ratio | 0.72 | ||
| Volatility % | 45.12 | ||
| 14-Day RSI | 48.47 | ||
| 14-Day ATR (₹) | 8.316001 | ||
| 20-Day SMA (₹) | 229.1625 | ||
| 12-1 Month Momentum % | -8.94 | ||
| 52-Week Range (₹) | 154.9 - 301.8 | ||
| Shares Outstanding (Mil) | 65.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jagsonpal Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jagsonpal Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 2.500000 Cash Dividend | 2025-09-12 | 248.60 (+1.47%) | ||
| 2.5:1 Stock Split | 2025-01-08 | 260.56 (+3.04%) | ||
| INR 2.000000 Cash Dividend | 2024-09-06 | 167.08 (-6.60%) |
Show
Entries
Jagsonpal Pharmaceuticals Ltd Frequently Asked Questions
What is Jagsonpal Pharmaceuticals Ltd(BOM:507789)'s stock price today?
The current price of BOM:507789 is ₹222.05. The 52 week high of BOM:507789 is ₹301.80 and 52 week low is ₹154.90.
When is next earnings date of Jagsonpal Pharmaceuticals Ltd(BOM:507789)?
The next earnings date of Jagsonpal Pharmaceuticals Ltd(BOM:507789) is .
Does Jagsonpal Pharmaceuticals Ltd(BOM:507789) pay dividends? If so, how much?
The Dividend Yield %  of Jagsonpal Pharmaceuticals Ltd(BOM:507789) is 1.13% (As of Today), Highest Dividend Payout Ratio of Jagsonpal Pharmaceuticals Ltd(BOM:507789) was 0.68. The lowest was 0.04. And the median was 0.27. The  Forward Dividend Yield % of Jagsonpal Pharmaceuticals Ltd(BOM:507789) is 1.13%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Jagsonpal Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers